These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 32107266)

  • 1. Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
    García-Beltran C; Cereijo R; Quesada-López T; Malpique R; López-Bermejo A; de Zegher F; Ibáñez L; Villarroya F
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32107266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a circulating marker of hepato-visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome - Evidence from randomized clinical trials.
    Malpique R; Sánchez-Infantes D; Garcia-Beltran C; Taxerås SD; López-Bermejo A; de Zegher F; Ibáñez L
    Pediatr Obes; 2019 May; 14(5):e12500. PubMed ID: 30653851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Circulating Levels of miR-451a in Girls with Polycystic Ovary Syndrome: Different Effects of Randomized Treatments.
    Díaz M; Bassols J; López-Bermejo A; de Zegher F; Ibáñez L
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31730174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPIOMET4HEALTH-efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial.
    Garcia-Beltran C; Malpique R; Andersen MS; Bas F; Bassols J; Darendeliler F; Díaz M; Dieris B; Fanelli F; Fröhlich-Reiterer E; Gambineri A; Glintborg D; López-Bermejo A; Mann C; Marin S; Obermayer-Pietsch B; Ødegård R; Ravn P; Reinehr T; Renzulli M; Salvador C; Singer V; Vanky E; Torres JV; Yildiz M; de Zegher F; Ibáñez L
    Trials; 2023 Sep; 24(1):589. PubMed ID: 37715279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat.
    de Zegher F; Díaz M; Villarroya J; Cairó M; López-Bermejo A; Villarroya F; Ibáñez L
    Sci Rep; 2021 Mar; 11(1):7018. PubMed ID: 33782413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
    Ibáñez L; Del Río L; Díaz M; Sebastiani G; Pozo ÓJ; López-Bermejo A; de Zegher F
    J Adolesc Health; 2017 Oct; 61(4):446-453. PubMed ID: 28712591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organokines and liver enzymes in adolescent girls with polycystic ovary syndrome during randomized treatments.
    Garcia-Beltran C; Peyrou M; Navarro-Gascon A; López-Bermejo A; de Zegher F; Villarroya F; Ibáñez L
    Front Endocrinol (Lausanne); 2024; 15():1325230. PubMed ID: 38818508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycystic ovary syndrome in adolescent girls.
    Ibáñez L; de Zegher F
    Pediatr Obes; 2020 Feb; 15(2):e12586. PubMed ID: 31663293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating follistatin concentrations in adolescent PCOS: Divergent effects of randomized treatments.
    Díaz M; de Zegher F; Ibáñez L
    Front Endocrinol (Lausanne); 2023; 14():1125569. PubMed ID: 36843579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome.
    Díaz M; Gallego-Escuredo JM; López-Bermejo A; de Zegher F; Villarroya F; Ibáñez L
    Int J Endocrinol; 2018; 2018():4192940. PubMed ID: 30123261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of half-dose spiomet treatment in girls with early puberty and accelerated bone maturation: a multicenter, randomized, placebo-controlled study protocol.
    Bassols J; de Zegher F; Diaz M; Carreras-Badosa G; Garcia-Beltran C; Puerto-Carranza E; Oliver-Vila C; Casano P; Franco CA; Malpique R; López-Bermejo A; Ibáñez L
    Trials; 2023 Jan; 24(1):56. PubMed ID: 36694227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota in adolescent girls with polycystic ovary syndrome: Effects of randomized treatments.
    Garcia-Beltran C; Malpique R; Carbonetto B; González-Torres P; Henares D; Brotons P; Muñoz-Almagro C; López-Bermejo A; de Zegher F; Ibáñez L
    Pediatr Obes; 2021 Apr; 16(4):e12734. PubMed ID: 32989872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
    Orbetsova M; Kamenov Z; Kolarov G; Zakharieva S; Khristov V; Atanasova I; Shigarminova R; Milcheva B; Genchev G
    Akush Ginekol (Sofiia); 2006; 45(7):16-28. PubMed ID: 17489164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
    Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
    Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.
    Ganie MA; Khurana ML; Eunice M; Gupta N; Gulati M; Dwivedi SN; Ammini AC
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2756-62. PubMed ID: 15181054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study.
    Rashid A; Ganie MA; Wani IA; Bhat GA; Shaheen F; Wani IA; Shrivastava M; Shah ZA
    Horm Metab Res; 2020 Feb; 52(2):89-94. PubMed ID: 32053841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS.
    Olaniyi KS; Oniyide AA; Adeyanju OA; Ojulari LS; Omoaghe AO; Olaiya OE
    Toxicol Appl Pharmacol; 2021 Jan; 411():115381. PubMed ID: 33359182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raised Thyroid-Stimulating Hormone in Girls with Polycystic Ovary Syndrome: Effects of Randomized Interventions.
    Garcia-Beltran C; Bassols J; Carreras-Badosa G; López Bermejo A; Ibáñez L; de Zegher F
    Horm Res Paediatr; 2023; 96(5):458-464. PubMed ID: 36649684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adolescent polycystic ovary syndrome without obesity: HOTAIR rs1443512 genotype relates to fat mass and to the redistribution of fat mass on low-dose pioglitazone.
    de Zegher F; Díaz M; Ibáñez L
    J Endocrinol Invest; 2024 Apr; 47(4):1037-1043. PubMed ID: 37805962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.